{"nctId":"NCT01005407","briefTitle":"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","startDateStruct":{"date":"2010-02"},"conditions":["Healthy"],"count":2452,"armGroups":[{"label":"HEPLISAV and/or Placebo","type":"EXPERIMENTAL","interventionNames":["Biological: HEPLISAV and/or Placebo"]},{"label":"Engerix-B(1)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Engerix-B"]}],"interventions":[{"name":"HEPLISAV and/or Placebo","otherNames":["Hepatitis B vaccine (recombinant), adjuvanted"]},{"name":"Engerix-B","otherNames":["Hepatitis B vaccine (recombinant)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* be 40 - 70 years of age, inclusive\n* be seronegative for hepatitis B surface antigen (HBsAg), antibody against hepatitis B surface antigen (anti-HBsAg), antibody against hepatitis B core antigen (anti-HBcAg), and human immunodeficiency virus (HIV)\n* be in good health in the opinion of the investigator, based upon medical history, physical examination, and laboratory evaluation\n* if female of childbearing potential, agree to consistently use a highly effective method of birth control from screening visit through the treatment phase, for up to 28 days after the last injection\n\nExclusion Criteria:\n\n* if female of childbearing potential, is pregnant, breastfeeding, or planning a pregnancy\n* has a history of or is considered by the investigator to be at high risk for recent exposure to HBV or HIV; for example, current intravenous drug use or has unprotected sex with known HBV/HIV positive partner\n* has a known history of autoimmune disease\n* has previously received any hepatitis B vaccine (approved or investigational)","healthyVolunteers":true,"sex":"ALL","minimumAge":"40 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Have a Seroprotective Immune Response","description":"Percentage of subjects who have a seroprotective immune response (anti-HBsAg antibody≥ 10 milli-international unit (mIU)/mL) 8 weeks after the last active dose of HEPLISAV™ compared to 8 weeks after the last active dose of Engerix-B®","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"70.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Local and Systemic Reaction to Injections","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.33","spread":null},{"groupId":"OG001","value":"18.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.10","spread":null},{"groupId":"OG001","value":"16.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"13.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.34","spread":null},{"groupId":"OG001","value":"22.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.38","spread":null},{"groupId":"OG001","value":"18.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"13.39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":78,"n":1968},"commonTop":["Nasopharyngitis"]}}}